J&J says APAC HQ will help 'co-create new global healthcare models'

10 May 2018

US healthcare giant Johnson & Johnson (NYSE: JNJ) has opened its new Asia Pacific (APC) headquarters amid much fanfare in Singapore.

According to a company statement, the regional headquarters will ‘lead collaborations and partnerships to co-create new global healthcare models which are at the forefront of innovation’.

More than 1,000 employees from J&J’s pharma, medical devices and consumer businesses will be based at the site, which will have design and leadership labs and what has been called a human performance institute (HPI) – promised to train 150,000 people in Singapore by 2020, including participants from outside J&J.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK